Search hospitals
>
Indiana
>
Indianapolis
Riley Hospital for Children
Claim this profile
Indianapolis, Indiana 46202
Global Leader in Cancer
Global Leader in Cystic Fibrosis
Conducts research for Solid Tumors
Conducts research for Brain Tumor
Conducts research for Neuroblastoma
551 reported clinical trials
39 medical researchers
Summary
Riley Hospital for Children is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Cancer, Cystic Fibrosis, Solid Tumors, Brain Tumor, Neuroblastoma and other specialties. Riley Hospital for Children is involved with conducting 551 clinical trials across 792 conditions. There are 39 research doctors associated with this hospital, such as Sandeep Batra, MD, Brian Weiss, MD, Melissa Bear, and Linda DiMeglio, MD.
Area of expertise
Cancer
Riley Hospital for Children has run 86 trials for Cancer. Some of their research focus areas include:
Cystic Fibrosis
Riley Hospital for Children has run 55 trials for Cystic Fibrosis. Some of their research focus areas include:
Top PIs
Sandeep Batra, MD
Riley Hospital for Children
8 years of reported clinical research
Brian Weiss, MD
Cincinnati Children's Hospital Medical Center
4 years of reported clinical research
Melissa Bear
Riley Hospital for Children
10 years of reported clinical research
Linda DiMeglio, MD
Indiana University - Riley Hospital for Children
3 years of reported clinical research
Clinical Trials running at Riley Hospital for Children
Crohn's Disease
Cancer
Cystic Fibrosis
Neuroblastoma
Leukemia
Testicular cancer
Brain Cancer
Wilms Tumor
Liver Cancer
Lymphoma
Anti-TNF Therapy
for Crohn's Disease in Children
Crohn's disease (CD) is a condition that causes inflammation (swelling, redness) of the lining and wall of the small intestine, large intestine, or both. CD may be associated with abdominal cramps/pain, diarrhea, blood in the stool, weight loss, or delayed growth in children. While the exact cause of CD is not certain it is thought that the immune system located in the intestine reacts abnormally to the large number of bacteria contained there. The investigators think that diet, exposure to antibiotics early in life, and having a family history of CD puts people at increased risk for developing CD. In order to decrease the inflammation doctors use what is called biologic therapy with anti-TNF molecules that can be given through an intravenous or shots. TNF is a chemical made by white blood cells that is involved in inflammation. When this type of treatment is given early after diagnosis it is more effective than when it is given later. The investigators have learned that it is important to give the optimum (ideal) amount of this medicine guided by certain blood tests. The investigators also know that not everyone responds to this therapy but do not understand the reasons for this variability between people. The CAMEO study has been started to help understand what factors are important in determining whether a child with CD completely heals the inflammation after anti-TNF therapy. The investigators will do that by measuring certain markers of inflammation in the blood and stool and by looking at a person's genes (DNA) and how inflammation is controlled in the intestine. These inflammation tests will be done before, during, and after one year of anti-TNF therapy. The investigators will determine how much healing has taken place by comparing the results of the colonoscopy and a special type of MRI that are both done before anti-TNF and then again one year later. The goal in treating CD is to heal both the lining and the wall of the intestine. Children ages 6-17 years who are thought to have CD and are about to undergo their diagnostic colonoscopy are eligible to be enrolled. If they are found to indeed have CD and start an anti-TNF medicine within 6 months they can continue in the study. There are no increased risks of participating in this study beyond those normally associated with having CD and its treatment. By better understanding why the bowel does or does not heal, doctors will be better able to provide personalized care.
Recruiting
3 awards
Phase 4
7 criteria
Risankizumab
for Pediatric Crohn's Disease
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to \< 18 years old who have had intolerance or inadequate response to other therapies. Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1(including Sub-cohort 1A) will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 118 pediatric participants with CD will be enrolled at around 100 sites worldwide. Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Recruiting
2 awards
Phase 3
Guselkumab
for Pediatric Crohn's Disease
This trial tests guselkumab, an anti-inflammatory medication, on children with Crohn's Disease who initially responded well to it. The goal is to see if the benefits last over several months by reducing immune system activity. Guselkumab has shown effectiveness in treating moderate-to-severe psoriasis and psoriatic arthritis.
Recruiting
2 awards
Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Riley Hospital for Children?
Riley Hospital for Children is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Cancer, Cystic Fibrosis, Solid Tumors, Brain Tumor, Neuroblastoma and other specialties. Riley Hospital for Children is involved with conducting 551 clinical trials across 792 conditions. There are 39 research doctors associated with this hospital, such as Sandeep Batra, MD, Brian Weiss, MD, Melissa Bear, and Linda DiMeglio, MD.
Where is Riley Hospital for Children located?
Riley Hospital for Children at IU Health is situated at 705 Riley Hospital Dr, Indianapolis, IN 46202.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Riley Hospital for Children, contact their department at 888.531.3004 (Monday-Friday, 8am - 4:30pm) or via email at financialcounseling@iuhealth.org. They provide support through Medicaid, IU Health Financial Assistance, and other health coverage programs. Indiana residents receiving care through emergency services, direct physician admission, or hospital transfers may qualify for extra assistance based on financial hardship.
What insurance does Riley Hospital for Children accept?
Riley Hospital for Children accepts a wide range of insurance plans, including Medicaid, The Healthy Indiana Plan (HIP), Hoosier Healthwise (HHW), COBRA, and private insurance plans such as Aetna, Anthem PPO/HMO, Blue Cross and Blue Shield, CIGNA HealthCare PPO/HMO, Humana ChoiceCare, and UnitedHealthcare. They participate in most major health plans in Indiana. Patients are advised to review their health plan provider directory and consult with their insurance company to confirm coverage.
What awards or recognition has Riley Hospital for Children received?
Riley Hospital for Children, located in Indianapolis, Indiana, is celebrated for its outstanding pediatric care, ranking among the nation's top children's hospitals in all 10 pediatric specialties according to U.S. News & World Report. It is also designated as a Level I Children's Surgery Center by the American College of Surgeons, showcasing its capability to offer comprehensive surgical care for infants and children with complex conditions.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.